Targeting BRD4 bromodomains and beyond: exploring new therapeutic frontiers

Area of Science:

• Molecular Biology
• Oncology
• Pharmacology

Background:

• Bromodomain-containing protein 4 (BRD4) is a key transcriptional regulator implicated in cancer and inflammation.
• Conventional bromodomain inhibitors (BETi) face limitations due to dose-limiting toxicities (DLTs) and emerging resistance.

Purpose of the Study:

• To review emerging evidence of BRD4's bromodomain-independent mechanisms in sustaining oncogenic programs.
• To discuss innovative therapeutic strategies beyond conventional BET inhibition for BRD4-driven diseases.

Main Methods:

• Review of preclinical and clinical data on BRD4-targeting strategies.
• Analysis of novel approaches including BRD4 degraders, nonbromodomain ligands, PTM disruptors, and condensate modulators.
• Discussion of chemically induced proximity (CIP) platforms and combination therapies.

Main Results:

• BRD4 possesses bromodomain-independent functions crucial for oncogenic programs.
• Emerging strategies like BRD4 degraders and CIP platforms show potential to overcome DLTs and resistance.
• Combination therapies, such as epigenetic-kinase inhibitors and BETi-immunotherapy, offer reduced toxicity and enhanced efficacy.

Conclusions:

• Innovative therapeutic strategies targeting BRD4's diverse mechanisms are crucial for overcoming clinical limitations.
• These novel approaches hold promise for developing more effective and safer treatments for BRD4-driven cancers and inflammatory diseases.
• Further research into these advanced therapeutic modalities is essential to establish new treatment frontiers.